U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H17FN8O2
Molecular Weight 408.3891
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NELOCIGUAT

SMILES

COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=C(F)C=CC=C3)C4=NC=CC=C24

InChI

InChIKey=FTQHGWIXJSSWOY-UHFFFAOYSA-N
InChI=1S/C19H17FN8O2/c1-30-19(29)24-14-15(21)25-17(26-16(14)22)13-11-6-4-8-23-18(11)28(27-13)9-10-5-2-3-7-12(10)20/h2-8H,9H2,1H3,(H,24,29)(H4,21,22,25,26)

HIDE SMILES / InChI

Molecular Formula C19H17FN8O2
Molecular Weight 408.3891
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Nelociguat, a soluble guanylate cyclase (sGC) activator, has been in phase II clinical trials by Bayer for the treatment of erectile dysfunction and heart failure. However, no recent development has been reported. Nelociguat is a direct soluble guanylate cyclase (sGC) stimulator that acts independently of nitric oxide (NO); has an EC50 of 353 nM on P-VASP formation in rat aortic smooth muscle cells. BAY 60-4552 is pharmacologically active major metabolite of Riociguat.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
PubMed

PubMed

TitleDatePubMed
Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure.
2013 May
Patents

Sample Use Guides

Heart Failure: Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
Route of Administration: Oral
Nelociguat has an EC50 of 353 nM on P-VASP formation in rat aortic smooth muscle cells.
Substance Class Chemical
Created
by admin
on Fri Dec 15 20:39:39 UTC 2023
Edited
by admin
on Fri Dec 15 20:39:39 UTC 2023
Record UNII
M2A18LL56O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NELOCIGUAT
INN   WHO-DD  
INN  
Official Name English
nelociguat [INN]
Common Name English
CARBAMIC ACID, N-(4,6-DIAMINO-2-(1-((2-FLUOROPHENYL)METHYL)-1H-PYRAZOLO(3,4-B)PYRIDIN-3-YL)-5-PYRIMIDINYL)-, METHYL ESTER
Common Name English
BAY 60-4552
Code English
Nelociguat [WHO-DD]
Common Name English
BAY-60-4552
Code English
RIOCIGUAT METABOLITE M1
Common Name English
CARBAMIC ACID, (4,6-DIAMINO-2-(1-((2-FLUOROPHENYL)METHYL)-1H-PYRAZOLO(3,4-B)PYRIDIN-3-YL)-5-PYRIMIDINYL)-, METHYL ESTER
Common Name English
METHYL (4,6-DIAMINO-2-(1-((2-FLUOROPHENYL)METHYL)-1H-PYRAZOLO(3,4-B)PYRIDIN-3-YL)PYRIMIDIN-5-YL)CARBAMATE
Systematic Name English
Code System Code Type Description
SMS_ID
300000034301
Created by admin on Fri Dec 15 20:39:39 UTC 2023 , Edited by admin on Fri Dec 15 20:39:39 UTC 2023
PRIMARY
FDA UNII
M2A18LL56O
Created by admin on Fri Dec 15 20:39:39 UTC 2023 , Edited by admin on Fri Dec 15 20:39:39 UTC 2023
PRIMARY
INN
9477
Created by admin on Fri Dec 15 20:39:39 UTC 2023 , Edited by admin on Fri Dec 15 20:39:39 UTC 2023
PRIMARY
PUBCHEM
11690019
Created by admin on Fri Dec 15 20:39:39 UTC 2023 , Edited by admin on Fri Dec 15 20:39:39 UTC 2023
PRIMARY
CHEBI
149785
Created by admin on Fri Dec 15 20:39:39 UTC 2023 , Edited by admin on Fri Dec 15 20:39:39 UTC 2023
PRIMARY
CAS
625115-52-8
Created by admin on Fri Dec 15 20:39:39 UTC 2023 , Edited by admin on Fri Dec 15 20:39:39 UTC 2023
PRIMARY
NCI_THESAURUS
C174685
Created by admin on Fri Dec 15 20:39:39 UTC 2023 , Edited by admin on Fri Dec 15 20:39:39 UTC 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
The protein binding of M1 is ~97% and is concentration independent.
Related Record Type Details
PARENT -> METABOLITE LESS ACTIVE
MAJOR
FECAL; PLASMA; URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC